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Analgesic and ulcerogenic properties have been studied for the copper(II) coordination complex of the nonsteroidal anti-
inflammatory drug Fenoprofen and imidazole [Cu(fen)
2
(im)
2
] (Cu: copper(II) ion; fen: fenoprofenate anion from Fenoprofen,
im: imidazole). A therapeutic dose of 28mg/kg was tested for [Cu(fen)
2
(im)
2
] and 21mg/kg was employed for Fenoprofen calcium,
administered by oral gavage in femalemice to compare the therapeutic properties of the new entity.The acetic acid inducedwrithing
test was employed to study visceral pain. The percentage of inhibition in writhing and stretching was 78.9% and 46.2% for the
[Cu(fen)
2
(im)
2
] and Fenoprofen calcium, respectively.This result indicates that the complex could bemore effective in diminishing
visceral pain.The formalin test was evaluated to study the impact of the drugs over nociceptive and inflammatory pain.The complex
is a more potent analgesic on inflammatory pain than the parent drug. Ulcerogenic effects were evaluated using a model of gastric
lesions induced by hypothermic-restraint stress. Fenoprofen calcium salt caused an ulcer index of about 79mm2 while the one
caused by [Cu(fen)
2
(im)
2
] was 22mm2. The complex diminished the development of gastric mucosal ulcers in comparison to the
uncomplexed drug. Possible mechanisms of action related to both therapeutic properties have been discussed.
1. Introduction
Inflammation is a physiological and biological response of
vascular tissues against harmful stimuli such as pathogens,
damaged cells, or irritants. It is a process which can be
classified as acute or chronic. In acute inflammation, an initial
response of the body against the harmful stimuli is initiated
bymovement of plasma and leukocytes from the blood to the
injured site, where a local inflammatory process is developed.
On the other hand, chronic inflammation is characterized by
the increment in the type of inflammatory cells present at the
site of inflammation. This sustained physiological response
in time causes simultaneous destruction and healing of the
injured tissue [1]. Some examples of chronic inflammatory
diseases are osteoarthritis, rheumatoid arthritis, degenerative
joint disease, and ankylosing spondylitis. These disorders
are associated with constant pain episodes and require the
intake of nonsteroidal anti-inflammatory drugs (NSAIDs)
as therapeutic agents in long-term treatment. These drugs
exert the inhibition of inflammation by blocking the action of
both isoforms of the cyclooxygenase enzyme (COX), known
as COX-1 and COX-2. COXs convert arachidonic acid into
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prostaglandin H2 which is then metabolized into various
prostaglandins, prostacyclins, and thromboxanes, which are
the molecular mediators that start the inflammatory process
[2]. The main problem related to these therapies is that they
cause systemic side effects associated with gastrointestinal
(GI), renal, and cardiovascular toxicity [3]. In particular,
long-term NSAIDs therapies employed in the treatment of
chronic inflammatory diseases produce GI toxicity due to the
generation of gastric ulcers [4].
Transition metal coordination complexes represent a
potential group of therapeutic agents with applications in
medicinal biochemistry. Several researches have been devel-
oped in the employment ofmetal complexes for the treatment
of many human diseases such as cancer, inflammatory disor-
ders, and infectious diseases, among others [5].
Copper represents a transition metal with proven anti-
inflammatory and analgesic properties [6], being a very
important oligoelement implicated in inflammatory pro-
cesses. Copper(II) complexes of NSAIDs as ligands generally
consist of a group of molecules with enhanced therapeutic
properties in comparison to the parent drug.
As previously mentioned, taking into account the GI
toxicity associatedwith the intake ofNSAIDs, the study of the
gastric ulcerogenic effect of some copper(II) complexes with
different ligands such as amino acids and NSAIDs has been
developed using different methods. As a result, it has been
found that the complexes tend to diminish the development
of gastric lesions associated with the therapy [7].
Although there exists a lot of research in the synthesis
and characterization of several copper(II)-complexes with
NSAIDs [3], in the last years, the research dealing with this
kind of compounds in terms of their therapeutic properties
[8–12] has been limited. Preexisting therapies would greatly
benefit from further in-depth study of these compounds, tak-
ing into account the low cost and simplicity of their synthesis
and their improved therapeutic properties in comparison to
the parent drug.
Fenoprofen [2-(3-phenoxyphenyl) propanoic acid]
(Scheme 1) is a NSAID with analgesic and antipyretic prop-
erties, being useful in the treatment of chronic inflammatory
diseases [13]. Because of its crystalline liquid properties, it
is difficult to obtain new and derivative formulations from
Fenoprofen. Our research group has carried out a thorough
study of the complexation of Fenoprofen to copper(II) metal
ion, being the first researchers to report the synthesis and
characterization of copper(II)-fenoprofenate complexes
[14, 15].
Ternary copper(II) complexes of Fenoprofen are promis-
ing therapeutic agents against inflammatory diseases because
of their enhanced anti-inflammatory and analgesic effects
compared to the parent Fenoprofen calcium salt [16, 17].
It was also demonstrated that two copper(II) complexes of
Fenoprofen do not produce toxicological effects in mice after
a subacute exposure, making this finding interesting for the
potential employment of the formulations in possible clinical
treatment.
In order to further contribute to the knowledge of
the enhanced therapeutic properties of Fenoprofen cop-
per(II) complexes, this study presents the antinociceptive and
O
CH3
COOH
Scheme 1: Molecular structure of Fenoprofen.
ulcerogenic activities of the first mononuclear copper(II)-
fenoprofenate complex containing the bioactive molecule
imidazole (im) (Figure 1). This coordination compound has
been proved to present improved anti-inflammatory activity
when compared to the uncomplexed Fenoprofen drug [13].
Therapeutic properties studied here were evaluated
employing the acetic acid-induced writhing test and the for-
malin test in terms of the analgesic properties.Meanwhile, the
ulcerogenic activity has been studied with the hypothermic-
restraint stress inducing ulcers method, to compare with the
uncomplexed commercial parent drug, Fenoprofen calcium
salt. Possible mechanisms of action by which the complex
could exert its enhanced therapeutic properties have been
postulated.
2. Materials and Methods
The methodology followed to synthesize the complex
[Cu(fen)
2
(im)
2
] has been performed as described in [17].
Briefly, a solution of 11.0mg (0.160mmol) of imidazole in
1mL of acetone was added to another solution containing
50.0mg (0.0400mmol) of [Cu
2
(fen)
4
(dmf)
2
]14 (dmf: N,N󸀠-
dimethylformamide) in acetone. The resulting blue solution
was kept under stirring for 30minutes and then diffused with
acetonitrile. After a few days at 4∘C, the obtained blue crystals
were washed with acetonitrile and air dried. The crystalline
sample achieved by this synthesis procedure ensures the
obtaining of a reproducible and pure compound suitable
for biomedical applications in vivo. Full physicochemical
characterization has been described in [17].
For the development of the study of the analgesic proper-
ties, healthy CF1 female mice, 8 weeks old, were employed.
They were obtained from the colony of the animal facility
from the Biology, Biochemistry, and Pharmacy Department
and maintained under constant conditions of temperature
(22 ± 1∘C) and humidity (70%), in a 12 h light: 12 hours
dark cycle (light on at 6:00) during all the experiment.
According to the bodyweight (approximately 30 g), theywere
randomly divided into different groups of 5-6 animals which
were acclimatized for a week before starting the experiment.
All animals had free access to tap water and standard diet
(Ganave, Ratas y Ratones, Alimentos Pilar S.A., Argentina)
throughout the experiment.
The study of the gastric ulcerogenic properties has been
carried out in healthy CF1 femalemice of about 30 g provided
by Facultad de Ciencias Veterinarias, Universidad Nacional
de La Pampa. They were randomly divided into different
groups of 6 animals; they had free access to tap water and
were fed ad libitum with a standard diet (Cooperacio´n,
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Figure 1: Molecular structure of the complex [Cu(fen)
2
(im)
2
].
Asociacio´n Cooperativas Argentinas, San vicente, Buenos
Aires, Argentina). Four hours before the beginning of the
bioassay, they were private of food.
The care and the handling of the animals were in accor-
dance with the internationally accepted standard Guide for
the Care and Use of Laboratory Animals [18] as adopted
and promulgated by the National Institute of Health. All
protocols were revised and approved by the affiliations where
the studies have been carried out.
2.1. In Vivo Antinociceptive Activity
2.1.1. Acetic Acid-Induced Abdominal Writhing. The test was
performed as described by Collier et al. [19] and Fontenele et
al. [20]. Nociception was induced by an intraperitoneal (i.p.)
injection of 0.6% acetic acid solution (10mL kg−1). Mice were
orally treated by gavage with 28mg kg−1 [Cu(fen)
2
(im)
2
],
and 1 hour later the acetic acid was injected. The vehicle
used for dissolution of complexes was 0.05% CMC-Na and
0.1% Tween 80. The control group received the vehicle and
the positive group received 21mg kg−1 Fenoprofen calcium
salt. Each quantity of drug administered was equivalent to
the therapeutic dose of 20mg kg−1 of Fenoprofen, taking
into account the good performance of this dose evaluated
in previous work developed by us related to the anti-
inflammatory properties of the drug and other derivative
copper(II)-Fenoprofen complexes [15–17]. Immediately after
the injection of acetic acid, each animal was isolated to an
individual box to be observed for 20 minutes. The number of
writhing and stretching was recorded. A writhe is indicated
by abdominal constriction and stretching by full extension of
hind limb.The results were expressed as inhibition percent in
the number of writhing and stretching, calculated employing
the formula [(1 − Tg)/Cg] × 100 with Tg being the number
of writhing and stretching recorded in the treated group and
Cg is the number of writhing and stretching recorded in the
control group.
2.1.2. Formalin Test. This test was carried out as described
by Hunskaar and Hole [21]. Twenty microliters of 2.5%
formalin were injected into the dorsal surface of the left
paw of mice 1 hour after oral administration by gavage of
28mg kg−1 [Cu(fen)
2
(im)
2
], 21mg kg−1 Fenoprofen salt, or
vehicle [0.05% CMC (carboxymethyl cellulose) and 0.1%
Tween 80]. The time that animals spent on licking and
biting the injected paw was recorded. On the basis of the
response pattern described by Tjolsen et al. [22], two distinct
periods of intensive licking activitywere identified and scored
separately.The nociceptive scores normally peaked 5minutes
after formalin injection (early phase) and 15–30 minutes after
the injection (late phase).
2.2. In Vivo Ulcerogenic Activity. The bioassay was car-
ried out in female mice employing the model of gastric
lesions induced by hypothermic-restraint stress described
by Levine [23] with some modifications. Animals were
fasted for 24 hours before the experiment and received
water ad libitum. They were orally per os administrated with
each compound: [Cu(fen)
2
(im)
2
], 28mg kg−1; Fenoprofen
calcium salt, 21mg kg−1; CuSO
4
, 12mg kg−1. The control
group received only the vehicle (0.05%CMC and 0.1% Tween
80). Each dose was calculated in order to obtain a final
therapeutic dose of Fenoprofen estimated in 20mg kg−1; for
CuSO
4
, the dose administered contained the same copper(II)
quantity of the corresponding coordination complex studied.
The purpose of including CuSO
4
in the study is to evaluate
the role of free copper(II) ions.
After one hour, mice were immobilized in cages with
individual cylindrical cells of 2.2 cm diameter and 10 cm in
length and immersed in water at 22∘C to the xiphoid cartilage
for 4.5 hours.
The stomachs of euthanized animals by cervical dislo-
cation were insufflated, removed, and fixed in formol 10%
solution. After 6 hours they were opened by the mayor
curvature and photographed. Digitalized photographs were
analyzed by an image analyzer in order to determine the
ulcerated area of each stomach. The total damaged stomach
surface (mm2) was expressed as the ulcer index (UI).
2.3. Statistical Analysis. Data obtained from each study were
tested using one-way ANOVA followed by Student’s t-test
when differences between groups were detected. Probability
values less than 0.05 were considered to be significant.
3. Results
Results obtained from acetic acid-induced writhing are
shown in Figure 2.
When acetic acid test was analyzed, the one-way
ANOVA reveled significant differences among the groups,
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Figure 2: Effects of Fenoprofen calcium salt (21mg kg−1) and
[Cu(fen)
2
(im)
2
] (28mg kg−1) on the acetic acid test. Both com-
pounds were administered by oral gavage 1 hour before the acetic
acid injection (i.p.). The number of writhing and stretching per
mouse was counted over a 20-minute period. Values are expressed
as means ± SEM; 𝑛 = 9 − 10. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 with respect
to the control group administered with the vehicle. #𝑃 < 0.01 with
respect to the Fenoprofen group.
F (18.27) = 24.5, 𝑃 < 0.001. Fenoprofen calcium salt and the
complex showed inhibitory effects on the writhing response
induced by acetic acid. Treatment with [Cu(fen)
2
(im)
2
] and
Fenoprofen salt significantly diminished the acetic acid-
induced writhing response compared with the control group
(𝑃 < 0.01 and 𝑃 < 0.05, resp.). The percentage of inhibition
was 78.9% and 46.2% for the complex and the uncomplexed
parent drug, respectively. It is remarkable the diminishing
in writhing and stretching caused by [Cu(fen)
2
(im)
2
] in
comparison to Fenoprofen calcium salt (𝑃 < 0.01).This result
indicates an excellent performance for the complexation of
the drug to copper(II) ions related to the analgesic effect.
Figure 3 shows results obtained for the study of the
analgesic properties evaluated by the formalin test inmice. In
this test, the one-wayANOVA revealed significant differences
among the groups, F (2.33) = 6.4, 𝑃 < 0.01 for the early
phase, and F (2.33) = 32.9, 𝑃 < 0.001 for the late phase.
The results obtained (Figure 3) showed that the time spent
on licking the injured paw was significantly attenuated in
the early phase by both Fenoprofen calcium salt and the
complex in comparison to the control group (𝑃 < 0.05). In
the second phase, the inhibitionwasmore significant for both
compounds (𝑃 < 0.01). Anyway, [Cu(fen)
2
(im)
2
] showed
a marked inhibition of licking responses in the late phase
with respect to the group administered with the Fenoprofen
calcium salt (𝑃 < 0.01). Therefore, the complex presented
a stronger effect than the corresponding calcium salt in the
inhibition of pain during the second phase of the assay
associated with the inflammatory pain.
Table 1 shows the ulcerogenic effect expressed as ulcer
index in mice induced by Fenoprofen calcium salt, free
copper(II) ions (administered as CuSO
4
), and the complex
[Cu(fen)
2
(im)
2
].
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Figure 3: Effects of Fenoprofen calcium salt and [Cu(fen)
2
(im)
2
]
on the formalin test. Values are expressed as the mean ± S.E.M. of
time that mice spent on licking and biting the injected paw in the
early phase (dark grey bar) and the late phase (gray bar). 𝑛 = 9-
10. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01, respectively, to the control group
administered with the vehicle. #𝑃 < 0.01, respectively, to the group
administered with the Fenoprofen calcium salt.
Table 1: Ulcerogenic effect caused by the tested compounds inmice.
Compound Ulcer index (UI)/mm2
Control 3.00
Fenoprofen calcium salt 79.0
Free copper(II) ions 11.5
[Cu(fen)
2
(im)
2
] 22.2
Regarding the study of the ulcerogenic effect of the
compounds, the employment of hypothermic restraintmodel
was introduced as an external stimulus for ulcer generation.
All the compounds studied incremented ulceration when
administered in comparison to the control group. Fenoprofen
calcium salt resulted in the most ulcerogenic compound with
respect to the control (𝑃 < 0.001). This fact is expectable
taking into account the gastrointestinal toxicity associated
with the intake of NSAIDs.
Administration of free copper(II) ions was implemented
to evaluate the role of copper(II) in ulcerogenesis, finding
that it produced the lowest ulceration index, indicating
that it would not cause severe ulcerogenic damage. On the
other hand, the copper(II)-fenoprofenate-imidazole complex
significantly diminished the damage to gastric mucosal in
comparison to the uncomplexed parent drug (𝑃 < 0.01),
as can be observed in the ulcer indexes reported in Table 1
obtained for the complex in comparison to Fenoprofen
calcium salt. Ulceration caused by [Cu(fen)
2
(im)
2
] resulted
in 3.6 times lower than the one caused by the uncomplexed
commercial drug. By this way, it is clearly demonstrated that
BioMed Research International 5
complexation of Fenoprofen to copper(II) ion reduced the
ulcerogenic effect of the free NSAID molecule.
Figure 4 shows representative photographs of mice’s
stomachs of each group administered with Fenoprofen cal-
cium salt, free copper(II) ions, and [Cu(fen)
2
(im)
2
]. The
decrease of ulcerated lesions in stomachs of mice treated with
the complex is observable.
4. Discussion
4.1. Analgesic Activity. Acetic acid-induced writhing is a
visceral pain model employed to evaluate antinociceptive
activity [24]. Intraperitoneal administration of acetic acid
causes the release of prostaglandins and sympathomimetic
mediators [25] which are activators of the nociceptive
mechanism. The complex studied significantly reduced the
number of abdominal constrictions and stretching of hind
limbs in mice. The percentage of inhibition was 78.9% for
[Cu(fen)
2
(im)
2
] and 46.2% for Fenoprofen salt. The visceral
analgesic action of the complex was significantly more
potent than Fenoprofen calcium salt at the same therapeutic
Fenoprofen dose (20mg kg−1). In this way, [Cu(fen)
2
(im)
2
]
presented a stronger analgesic activity for visceral pain.
Okuyama et al. have studied the effect of free copper(II)
in analgesia [26]. Through the acetic acid-induced writhing
test, they have found that copper salts [Cu(chloride)
2
and
Cu(acetate)
2
], even when presenting analgesic activity, are
not as effective as the corresponding copper(II) complexes
with NSAIDs such as indomethacin, aspirine, and niflumic
acid.
The formalin test is employed as a model for nociceptive
pain [27, 28] being useful for the evaluation of nociceptive
and inflammatory pain. Animals present two distinct noci-
ceptive behaviour phases: the early phase (phase 1) initiates
immediately after formalin injection and lasts about 3–5
minutes while the late phase (phase 2) is initiated 15–20
minutes after injection and lasts about 20–40 minutes. The
development of phase 1 results from the chemical stimulation
of nociceptors and nerves by formalin. The nociception
produced in phase 2 is a result of chemical insult resulting
in tissue damage [24] with the concomitant generation of
inflammation mediators [22]. NSAID agents have little effect
on the early phase but they reduce the nociceptive behavior
of licking and biting in the late phase [21].
As expected, Fenoprofen calcium salt and [Cu(fen)
2
(im)
2
] presented little effect on the early phase of the formalin
test, taking into account the effect of NSAIDs, but it reduced
the nociceptive behaviour in the late phase. This reduction
is associated with the inhibition of COX-2 with concomitant
blockage of prostaglandin secretion. The complex showed
remarkable inhibition of licking responses in the late phase
in comparison with the Fenoprofen salt.
4.2. Mechanisms Proposed for Enhanced Analgesic Proper-
ties of the Complex. In previous work by this research
team, it has been demonstrated that [Cu(fen)
2
(im)
2
] exerts
enhanced anti-inflammatory properties in comparison with
Fenoprofen as well as presenting superoxide dismutase
(SOD) mimetic activity [17]. SOD enzyme is a copper-
zinc metalloprotein encouraged to catalyze the conversion
of the oxidative superoxide anion (O
2
−⋅), diminishing in
this way the oxidative stress present in the pathophysiology
of inflammatory processes [29]. The SOD mimetic activity
imparts antioxidant properties to the complex, being this
characteristic very important in the inflammatory process, as
it contributes to diminish inflammation.This property, added
to the known effect of NSAID in blocking inflammation
by inhibiting COX-2, would increase the anti-inflammatory
activity of the coordination complex versus the free NSAID.
This activity would be responsible for the better performance
regarding the decrease in nociceptive pain in the late phase
of the formalin test compared to Fenoprofen calcium salt,
making [Cu(fen)
2
(im)
2
] a better analgesic drug. Scheme 2
illustrates the proposed mechanism by which the complex
exerts increased analgesic properties in comparison to Feno-
profen.
The presence of copper in the complex may largely
explain the enhanced therapeutic properties of [Cu(fen)
2
(im)
2
]. Nevertheless, other plausible mechanisms of action
exist by which the copper complex could increment the
antinociceptive effect of Fenoprofen: (I) copper complexes
could act as transporters of copper(II) to the site of inflam-
mation, where the metal ion is necessary as a cofac-
tor of some enzymes such as superoxide dismutase [30].
The incremented bioavailability of copper(II) ion by the
copper(II) coordination complex and its SODmimetic activ-
ity would be two factors implicated in the reduction of
inflammationwhichwould concomitantly diminish the noci-
ceptive effect. (II) Complexed forms of copper(II) would
facilitate absorption and tissue distribution of copper as well
as the associated ligands, thus incrementing their bioavail-
ability [31]. Taking into account this possible mechanism, the
copper(II)-Fenoprofenate-imidazole complex studied here
could be acting as a moiety that is more absorbable than
the uncomplexed parent drug, incrementing Fenoprofen
bioavailability, thus potentiating its anti-inflammatory activ-
ity and, in this way, the antinociceptive effect.
It is important to mention that oral administration of
the complex would not interfere with the analgesic activity,
taking into account that the therapeutic effect of the complex
is higher compared to that of the uncomplexed Fenoprofen.
If stomach digestion promoted dissociation of the complex,
the observation of enhanced analgesic activity would not be
possible, considering that the Fenoprofenate anion concen-
tration is equivalent to the amount in the Fenoprofen calcium
salt and [Cu(fen)
2
(im)
2
] doses studied.
4.3. Ulcerogenic Effect. NSAIDs cause GI mucosa damage
by several mechanisms: direct irritation to the epithelium,
reducing mucosa blood flow, interfering with the normal
repair of superficial injury, or inhibiting prostaglandins
synthesis by blocking the activity of cyclooxygenase enzyme
(COX) [32]. There exist two COX isoenzymes: COX-1, a
house-keeping enzyme, and COX-2, primarily induced by
inflammatory stimuli in various cells. NSAIDs exert their
anti-inflammatory activity inhibiting COX-2 isoenzyme,
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Figure 4: Mice stomachs with gastric lesions induced by Fenoprofen calcium salt, free copper(II) ions, and the coordination copper(II)
complex (in comparison to the control group). The presence of milder injuries in the stomachs belonging to the group treated with the
complex rather than those administered with calcium Fenoprofen is evident.
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] in comparison to the uncomplexed commercial
parent drug (COX-2: cyclooxygenase-2; PG: prostaglandins; SOD: superoxide dismutase).
while the downregulation of COX-1 is associated with gastric
ulceration [33].
Hypothermic-restraint stress inducing ulcers method is
commonly used for the evaluation of antiulcer activity in ani-
mals [34].The possible mechanism involved in the induction
of ulcers could be the increase of histamine release which
enhances acid secretion [35] and reduces mucus production
[36]. Alterations in gastric mucosal microcirculation and
abnormal motility are also proposed as pathogenic mecha-
nisms caused by stress-induced gastric mucosal lesions [37].
Nevertheless, the most important factor in the genesis of
stress ulcer is the vagal over-activity that increases gastric acid
secretion.
Taking into account the mechanism proposed for ulcero-
genesis caused by the NSAIDs, it seems fitting to analyze the
possible mechanism exerted by the copper(II)-fenoprofenate
complex to protect the stomach against mucosal damage.
Fenoprofen produces a great area of mucosal damage, prob-
ably by the mechanisms previously described for all NSAIDs
in general. Even when [Cu(fen)
2
(im)
2
] increases ulceration
in comparison to the control group, it exhibits a lower
ulcerogenic effect in comparison to Fenoprofen calcium salt.
Thus, the lower ulcerogenic action of [Cu(fen)
2
(im)
2
] in
comparison to uncomplexed parent drug could be due to
various reasons: (I) the association between copper(II) and
Fenoprofen would protect the gastric epithelium against the
direct irritation caused by free Fenoprofen; (II) Its antioxidant
properties, due to the superoxide dismutase enzyme (Cu-
SOD) mimetic activity, could be favourable to diminish
lesions associated with tissue injury. As mentioned above,
[Cu(fen)
2
(im)
2
] has the property of being a mimetic of the
(Cu-SOD). This enzyme takes part in many oxidative stress
processes because it catalyzes the scavenging of superoxide
anionO
2
−⋅ acting as a relevant physiological antioxidant; (III)
copper(II) complexes present more lipophilic character than
the corresponding uncomplexed ligands and have proven
gastric antisecretory activity [26]. The higher lipophilicity of
[Cu(fen)
2
(im)
2
] would increase the absorption of this com-
plex by the stomach cells, thus facilitating its antisecretory
activity in situ, and this would result in decreased gastric
acidity.
5. Concluding Remarks
In this work, the antinociceptive and the ulcerogenic prop-
erties of [Cu(fen)
2
(im)
2
] have been studied. The copper(II)
complex presented enhanced analgesic activity when com-
pared to Fenoprofen due to its potent anti-inflammatory
8 BioMed Research International
activity. It also exerted a lower ulcerogenic action than
the parent drug, diminishing the development of gastric
mucosal ulceration. With these results and based on our
previous experience, it is possible to postulate that both
the enhanced analgesic activity compared to Fenoprofen
calcium salt and the reduced ulcerogenic effect of the complex
studied here could be attributed to the antioxidant activity
imparted by the presence of copper(II) ion in its structure.
The present study permits to establish that this complex is a
promising alternative therapeutic agent against conventional
therapy with NSAIDs, not only because of its biomedical
properties but also because of its easy and cheap obtention.
The presence of copper(II) in the molecular structure of
the complex is responsible for enhancing the therapeutic
properties of uncomplexed Fenoprofen. This metal ion plays
a crucial role in inflammation and pain associated processes.
[Cu(fen)
2
(im)
2
] could be applied as a therapeutic agent in the
medical treatment of chronic inflammatory diseases because
it prevents side effects associated with the therapy with
NSAIDs such as ulcerogenesis, and because it is amore potent
analgesic agent than Fenoprofen.
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